Predicting the outcome of ankylosing spondylitis therapy

Predicting the outcome of ankylosing spondylitis therapy

Objectives To create a model that provides a potential basis for candidate selection for anti-tumour necrosis factor (TNF) treatment by predicting future outcomes relative to the current disease profile of individual patients with ankylosing spondylitis (AS). Methods ASSERT and GO–RAISE trial data (...

Полное описание

Сохранить в:

Библиографические подробности
Главные авторы:	Nathan Vastesaeger, Désirée van der Heijde, Robert D. Inman, Yanxin Wang, Atul Deodhar, Benjamin Hsu, Mahboob U. Rahman, Ben A. C. Dijkmans, Piet Geusens, Bert Vander Cruyssen, Eduardo Collantes‐Estévez, Joachim Sieper, Jürgen Braun
Формат:	Artigo
Язык:	английский
Опубликовано:	2011
Online-ссылка:	https://doi.org/10.1136/ard.2010.147744 https://ard.bmj.com/content/annrheumdis/70/6/973.full.pdf
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!

Схожие документы

Predicting the outcome of ankylosing spondylitis therapy
по: Vastesaeger, Nathan, и др.
Опубликовано: (2011)

Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery
по: Bert Vander Cruyssen, и др.
Опубликовано: (2009)

Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis
по: van der Heijde, Désirée, и др.
Опубликовано: (2019)

Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis
по: Désirée van der Heijde, и др.
Опубликовано: (2018)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
по: Braun, Jürgen, и др.
Опубликовано: (2011)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
по: Jürgen Braun, и др.
Опубликовано: (2011)

Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab
по: Wagner, Carrie, и др.
Опубликовано: (2011)

Ankylosing spondylitis: an overview
по: Joachim Sieper, и др.
Опубликовано: (2002)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study
по: Deodhar, Atul, и др.
Опубликовано: (2015)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study
по: Atul Deodhar, и др.
Опубликовано: (2014)

Anti-tumour necrosis factor α therapy for ankylosing spondylitis: international experience
по: Braun, J, и др.
Опубликовано: (2002)

The Effect of Golimumab Therapy on Disease Activity and Health-related Quality of Life in Patients with Ankylosing Spondylitis: 2-year Results of the GO-RAISE Trial
по: Désirée van der Heijde, и др.
Опубликовано: (2014)

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
по: Dominique Baeten, и др.
Опубликовано: (2015)

First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis
по: Jürgen Braun, и др.
Опубликовано: (2005)

Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study
по: Jürgen Braun, и др.
Опубликовано: (2011)

Fifty years after the discovery of the association of HLA B27 with ankylosing spondylitis
по: Jürgen Braun, и др.
Опубликовано: (2023)

Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study
по: Inman, Robert D., и др.
Опубликовано: (2016)

Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study
по: Xenofon Baraliakos, и др.
Опубликовано: (2023)

The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
по: Braun, Jürgen, и др.
Опубликовано: (2014)

The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
по: Jürgen Braun, и др.
Опубликовано: (2013)

The epidemiology of ankylosing spondylitis and the commencement of anti‐TNF therapy in daily rheumatology practice
по: Cruyssen, Bert Vander, и др.
Опубликовано: (2007)

The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice
по: Bert Vander Cruyssen, и др.
Опубликовано: (2007)

Spinal Radiographic Changes in Ankylosing Spondylitis: Association with Clinical Characteristics and Functional Outcome
по: Annelies Boonen, и др.
Опубликовано: (2009)

Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies
по: Braun, Jürgen, и др.
Опубликовано: (2018)

The epidemiology of osteoporosis and fractures in ankylosing spondylitis
по: Sambrook, Philip N., и др.
Опубликовано: (2012)

The epidemiology of osteoporosis and fractures in ankylosing spondylitis
по: Philip N. Sambrook, и др.
Опубликовано: (2012)

Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study
по: Braun, Jürgen, и др.
Опубликовано: (2011)

ASAS/EULAR recommendations for the management of ankylosing spondylitis
по: Zochling, J, и др.
Опубликовано: (2006)

Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial
по: Désirée van der Heijde, и др.
Опубликовано: (2022)

Etanercept in the Longterm Treatment of Patients With Ankylosing Spondylitis
по: Ben A. C. Dijkmans, и др.
Опубликовано: (2009)

Ankylosing spondylitis: an overview
по: Sieper, J, и др.
Опубликовано: (2002)

Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis
по: Sudha Visvanathan, и др.
Опубликовано: (2008)

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
по: Braun, J, и др.
Опубликовано: (2011)

Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches.
по: Jürgen Braun, и др.
Опубликовано: (2002)

Definition of disease duration in ankylosing spondylitis: reassessing the concept
по: Davis, J C, и др.
Опубликовано: (2006)

Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis
по: Désirée van der Heijde, и др.
Опубликовано: (2007)

Staging of patients with ankylosing spondylitis: a preliminary proposal
по: Braun, J, и др.
Опубликовано: (2002)

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial
по: Désirée van der Heijde, и др.
Опубликовано: (2008)

Determinants of hyperkyphosis in patients with ankylosing spondylitis
по: Vosse, D, и др.
Опубликовано: (2006)

Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study
по: Jürgen Braun, и др.
Опубликовано: (2016)